Effect of glycation on the properties of lipoprotein(a)

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 15, Issue 3, 1995, Pages 385-391

  Makino, Kazuhiko ^a   Furbee Jr , James W ^a   Scanu, Angelo M ^a   Fless, Gunther M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

charge; degradation; diabetes; lysine binding; macrophages

Indexed keywords

LIPOPROTEIN; LYSINE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CASE REPORT; DIABETES MELLITUS; FEMALE; HUMAN; MACROPHAGE; MALE; PRIORITY JOURNAL;

EID: 0028943935     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.15.3.385     Document Type: Article

References (48)

1. Scanu AM, Fless GM. Lipoprotein (a): heterogeneity and biological relevance. J Clin Invest. 1990;85:1709-1715.
2. Schernthaner G, Kostner GM, Dieplinger H, Prager R, Muelhauser I. Apolipoproteins (A-I, A-II, B), Lp(a) lipoprotein and lecithin: cholesterol acyltransferase activity in diabetes mellitus. Atherosclerosis. 1983;49:277-293.
3. Mertz DP, Buervenich K. Unterschiedliche Werte von Lipoprotein Lp(a) bei erwachsenen Diabetikern in Abhaengigkeit von der Therapieform. Klin Wochenschr. 1985;63:648-650.
4. Takegoshi T, Haba T, Hirai J, Kitoh C, Saga T, Yamazaki YHM. Alterations of lipoprotein(a) in patients with diabetic nephropathy. Atherosclerosis. 1990;83:99-100.
5. Jenkins A, Steele J, Janus E, Best J. Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes. 1991;40:787-790.
6. Levitsky L, Scanu AM, Gould SH. Lipoprotein(a) levels in black and white children and adolescents with IDDM. Diabetes Care. 1991;14:283-287.
7. Winocour PH, Bathnagar D, Ishola M, Arrol S, Durrington PN. Lipoprotein(a) and microvascular disease in type I (insulin-dependent) diabetes. Diabet Med. 1991;8:922-927.
8. Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P. Lipoprotein (a) levels in diabetes-mellitus: relationship to metabolic control. Ann Intern Med. 1992;117:42-47.
9. Csaszar A, Dieplinger H, Sandholzer C, Karadi I, Juhasz E, Drexel H, Halmos T, Romics L, Patsch JR, Utermann G. Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus. Diabetologia. 1993;36:47-51.
10. Dubrey SW, Reaveley DA, Leslie DG, Odonnell M, Oconnor BM, Seed M. Effect of insulin-dependent diabetes mellitus on lipids and lipoproteins: a study of identical twins. Clin Sci. 1993;84:537-542.
11. Haffner SM, Morales PA, Gruber MK, Hazuda HP, Stern MP. Cardiovascular risk factors in non-insulin-dependent diabetic subjects with microalbuminuria. Arterioscler Thromb. 1993;13:205-210.
12. Heesen BJ, Wolffenbuttel BHR, Leurs PB, Sels JPJE, Menheere PPCA, Jacklebeckers SEC, Kruseman ACN. Lipoprotein(a) levels in relation to diabetic complications in patients with non-insulin-dependent diabetes. Eur J Clin Invest. 1993;23:580-584.
13. Makino K, Josephson MA, Fellner SK, Scanu AM. Plasma lipoprotein(a) levels in patients having chronic renal failure with and without diabetes-mellitus. Atherosclerosis. 1993;98:255-256.
14. Ritter MM, Loscar M, Richter WO, Schwandt P. Lipoprotein(a) in diabetes-mellitus. Clin Chim Acta. 1993;214:45-54.
15. West KM. Hyperglycaemia as a cause of long-term complications. In: Keen H, Jarrett RJ, eds. Complications of Diabetes. London, England: Edward Arnold; 1982:13-18.
16. Curtiss LK, Witztum JL. Plasma apolipoproteins AI, All, B, CI, and E are glucosylated in hyperglycemic diabetic subjects. Diabetes. 1985;34:452-461.
17. Lyons TJ, Klein RL, Baynes JW, Stevenson HC, Lopes-Virella MF. Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from type I (insulin-dependent) diabetic patients: the influence of non-enzymatic glycosylation of low-density lipoproteins. Diabetologia. 1987;30:916-923.
18. Lopes-Virella MF, Klein RL, Lyons TL, Stevenson HC, Witztum JL. Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes. 1988;37:550-557.
19. Steinbrecher U, Witztum JL. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes. 1984;33:130-134.
20. Snyder ML, Polacek D, Scanu AM, Fless GM. Comparative binding and degradation of lipoprotein(a) and low density lipoprotein by human monocyte derived macrophages. J Biol Chem. 1992;267:339-346.
21. Fless GM, ZumMallen ME, Scanu AM. Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein(a). J Biol Chem. 1986; 261:8712-8718.
22. Fless GM, Snyder ML, Scanu AM. Enzyme-linked immunoassay for Lp(a). J Lipid Res. 1989;30:651-662.
23. Fless GM, ZumMallen ME, Scanu AM. Isolation of apolipoprotein(a) from lipoprotein(a). J Lipid Res. 1985;26:1224-1229.
24. Scanu AM, Miles LA, Fless GM, Pfaffinger D, Eisenbart JE, Jackson E, Hoover-Plow JL, Brunck T, Plow EF. Rhesus monkey lipoprotein(a) binds to lysine Sepharose and U937 monocytoid cells less efficiently than human lipoprotein(a): evidence for the dominant role of kringle 4-37. J Clin Invest. 1993;91:283-291.
25. Means GE, Feeney RE. Chemical Modification of Proteins. San Francisco, Calif: Holden-Day, Inc; 1971:217.
26. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem. 1992;267:4143-4151.
27. McFarlane AS. Efficient trace-labeling of proteins with iodine. J Biol Chem. 1958;182:53-57.
28. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoproteins, I: preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972;260:212-221.
29. Fogelman AM, Seager J, Hokom M, Edwards PA. Separation of and cholesterol synthesis by human lymphocytes and monocytes. J Lipid Res. 1979;20:379-388.
30. Innerarity TL, Pitas RE, Mahley RW. Lipoprotein-receptor interactions. Methods Enzymol. 1986;129:542-565.
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193:265-275.
32. Markwell MAK, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978;87:206-210.
33. Goldstein JL, Basu SK, Brown MS. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 1983;98:241-260.
34. Brownlee M. Nonenzymatic glycosylation of macromolecules: prospects of pharmacologie modulation. Diabetes. 1992;41(suppl 2): 57-60.
35. McLean J, Tomlinson J, Kuang W, Eaton D, Chen E, Fless G, Scanu A, Lawn R. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature. 1987;300:132-137.
36. Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes. 1982;31:283-291.
37. Guggliuci-Creriche A, Stahl AJC. Glycation and oxidation of human low density lipoproteins reduces heparin binding and modifies charge. Scand J Clin Lab Invest. 1993;53:125-132.
38. Scott J. The molecular and cell biology of apolipoprotein-B. Mol Biol Med. 1989;6:65-80.
39. Gonen B, Baenziger J, Schonfeld G, Jacobson D, Farrar P. Non-enzymatic glycosylation of low density lipoproteins in vitro. Diabetes. 1981;30:875-878.
40. Sasaki J, Cottam GL, Glycosylation of LDL decreases its ability to interact with high affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma. Biochim Biophys Acta. 1982;713:199-207.
41. Snyder ML, Hay RV, Whitington PF, Scanu AM, Fless GM. Binding and degradation of lipoprotein(a) and LDL by primary cultures of human hepatocytes: comparison with cultured human monocyte-macrophages and fibroblasts. Arterioscler Thromb. 1994;14:770-779.
42. Rainwater DL, Maccluer JW, Stern MP, Vandeberg JL, Haffner SM. Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size. Diabetes. 1994;43:942-946.
43. Schleicher E, Olgemulier B, Schon J, Durst T, Wieland OH. Limited nonenzymatic glucosylation of low-density lipoprotein does not alter its catobolism in tissue culture. Biochim Biophys Acta. 1985;846:226-233.
44. Haffner SM. Lipoprotein(a) and diabetes: an update. Diabetes Care. 1993;16:835-840.
45. Dubrey SW, Reaveley DR, Seed M, Lane DA, Ireland H, O'Donnell M, O'Connor B, Noble MI, Leslie RDG. Risk factors for cardiovascular disease in IDDM: a study of identical twins. Diabetes. 1994;43:831-835.
46. Maser RE, Usher D, Becker DJ, Drash AL, Kuller LH, Orchard TJ. Lipoprotein(a) concentration shows little relationship to IDDM complications in the Pittsburgh Epidemiology of Diabetes Complications Study cohort. Diabetes Care. 1993;16:755-758.
47. Smith EB, Crosbie L. Does lipoprotein(a) (Lp(a)) compete with plasminogen in human atherosclerotic lesions and thrombi? Atherosclerosis. 1991;89:127-136.
48. Knott TJ, Pease RJ, Powell LM, Wallis SC, Rall SC Jr, Innerarity TL, Blackhart B, Taylor WH, Marcel Y, Milne R, Johnson D, Fuller M, Lusis AJ, McCarthy BJ, Mahley RW, Levy-Wilson B, Scott J. Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature. 1986; 323:734-738.